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ABSTRACT: A series of dinuclear octahedral platinum(IV) 
complexes trans, trans, trans-[{Pt(N3)2(py)2(OH)-
(OC(O)CH2CH2C(O)NH)}2R] containing pyridine (py) and 
bridging dicarboxylate (R = -CH2CH2- (1); trans-1,2-C6H10- (2); p-
C6H4- (3); -CH2CH2CH2CH2- (4)) ligands have been synthesized 
and characterized, including the x-ray crystal structures of 
complexes 1·2MeOH and 4, the first photoactivatable dinuclear 
platinum(IV) complexes with azido ligands. The complexes are 
highly stable in the dark, but upon photoactivation with blue light 
(420 nm) they release the bridging ligand and mononuclear 
photoproducts. On irradiation with blue light (465 nm) they 
generate azidyl and hydroxyl radicals, detected using a DMPO EPR 
spin-trap, accompanied by the disappearance of the LMCT (N3→Pt) 
band at ca. 300 nm. The dinuclear complexes are photocytotoxic to 
human cancer cells (465 nm, 4.8 mW/cm2, 1 h), including A2780 
human ovarian and oesophageal OE19 cells with IC50 values of 
8.8–78.3 μM, whereas cisplatin is inactive under these conditions. 
Complexes 1, 3 and 4 are notably more photoactive towards 
cisplatin-resistant ovarian A2780cis compared to A2780 cells. 
Remarkably, all the complexes were relatively non-toxic toward 
normal cells (MRC5 lung fibroblasts), with IC50 values >100 μM, 
even after irradiation. The introduction of the aromatic bridging 
ligand (3) enhanced cellular uptake significantly. The populations 
in the stages of the cell cycle remained unchanged on treatment 
with complexes in the dark, while the population of the G2/M phase 
increased on irradiation, suggesting that DNA is a target for these 
photoactivated dinuclear platinum(IV) complexes. LC-MS data 
show that the photodecomposition pathway of the dinuclear 
complexes results in the release of two molecules of mononuclear 
platinum(II) species. As a consequence, DNA binding of the 
dinuclear complexes after photoactivation in cell-free media is, in 
several respects, qualitatively similar to that of the photoactivated 
mononuclear complex FM-190. After photoactivation, they were 
two-fold more effective in quenching fluorescence of EtBr bound 
to DNA, forming DNA interstrand cross-links and unwinding DNA 
compared to photoactivated FM-190.  
INTRODUCTION 
  Photoactivation is a promising effective and non-invasive 
chemotherapeutic strategy.1-4 Photochemotherapy using 
appropriate platinum complexes has the potential to overcome 
some of the limitations of conventional cisplatin therapy, including 
poor pharmacokinetics, dose-limiting side effects, restricted 
spectrum of anticancer activity, high incidence of resistance, and 
lack of normal-cell discrimination.5,6 The application of oxygen-
dependent photodynamic therapy (PDT) is limited owing to the low 
concentration of O2 in hypoxic tumours, together with the need for 
diffusion of O2 from adjacent tissues.7 Photoactivated 
chemotherapy (PACT), in contrast, is less dependent on oxygen for 
cytotoxicity and provides a new avenue to anticancer drug design. 
Octahedral, low-spin 5d6 PtIV complexes are usually considered 
to be prodrugs, since they are kinetically more inert than their PtII
counterparts under biological conditions.8-10 Photoactivatable PtIV
prodrugs can exhibit high dark stability and potential 
photocytotoxicity,11-13 examples include diazido- PtIV complexes 
containing various non-leaving amines and axial substituents.14-20
Among them, trans, trans, trans-[Pt(N3)2(OH)(py)2] (FM-190) is 
highly potent,21,22 has good aqueous solubility, is relatively stable 
in cell culture media and towards reactions with the abundant 
intracellular tripeptide glutathione (GSH, γ-L-Glu-L-Cys-Gly), and 
can be activated by UVA, blue (420 nm) and green (500±30 nm) 
light, achieving low micromolar IC50 values even in cisplatin-
resistant cell lines, with a high phototoxicity index. Not only does 
the platinum center become reactive on photoreduction, but in 
addition azidyl radicals can be released by FM-190 in a manner 
controllable by the amino acid L-Trp.23
Axial ligands in diazido-PtIV complexes normally act as leaving 
groups upon reduction to PtII and greatly influence the reduction 
potential of PtIV. Derivatisation of an axial ligand can be used to 
improve pharmacological properties without interfering with the 
ultimate mode of action of the active PtII species or the potential 
production of other reactive species. Several studies have been 
carried out previously on the conjugation of FM-190 to functional 
fragments, including αvβ3 and αvβ5 integrin-selective RGD-
2 
containing peptides,24 RNA-binding guanidinoneomycin,25
TEMPO radical26, upconversion-luminescent nanoparticles27 and
G-quadruplex G4K+ borate hydrogels.28 For the former two 
conjugates, the selectivity and cellular uptake toward specific 
cancer cells was remarkably enhanced, while for the prodrug with 
TEMPO, azidyl and TEMPO radicals were released upon 
irradiation with blue light (420 nm), accompanied by the formation 
of toxic PtII species, resulting in improved cytotoxicity. 
Upconversion-luminescent nanoparticles enable photoactivation 
with near-infrared light, and hydrogels allow treatment of surface 
cancers with minimal damage to normal tissues. 
Polynuclear platinum complexes have attracted much attention 
owing to their unique biological properties, including coordinative 
binding to DNA bases and interaction of the phosphodiester linker 
through electrostatic and hydrogen-bonding effects.29 The pre-
association of polynuclear platinum complexes with DNA prior to 
coordinate bond formation can significantly affect the kinetics of 
cross-link formation,30-33 which distinguishes them from their 
mononuclear counterparts. The trinuclear complex [{trans-
PtCl(NH3)2}2(μ-trans-Pt(NH3)2{NH2(CH2)6NH2}2)]4+ (BBR3464) 
underwent phase I and II human clinical trials as a promising 
anticancer platinum drug.34-36
In order to investigate structure-activity relationships related to 
the modification of the axial ligands of diazido-PtIV complexes and 
improve the antiproliferative activity of photoactivatable PtIV
prodrugs, we have synthesized and characterized a series of 
dinuclear platinum(IV) complexes of the type trans, trans, trans-
[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)NH)}2R] (R = -CH2CH2- 
(1); trans-1,2-C6H10- (2); p-C6H4- (3); -CH2CH2CH2CH2- (4)). The 
x-ray crystal structures of complexes 1·2MeOH and 4 were 
determined. These appear to be the first photoactivatable dinuclear 
platinum(IV) complexes containing azides to be reported. Their 
photodecomposition, photoreactions with 5′-guanosine 
monophosphate (5′-GMP), interaction with DNA, 
photocytotoxicity, cellular accumulation, and effect on cancer cell 
cycle distribution were studied. The chemical and biological 
behaviour of these complexes containing two platinum centers and 
four azides in one molecule are compared to related mononuclear 
diazido complexes, including the influence of the nature of the 
bridging ligand. 
EXPERIMENTAL SECTION 
Materials and instruments. O-(Benzotriazol-1-yl)-N, N, N’, 
N’-tetramethyluronium tetrafluoroborate (TBTU) was purchased 
from Merck, Pyridine was from Fischer Scientific UK, ct-DNA, 
K2PtCl4, NaN3, H2O2 (30%), succinic anhydride and other 
chemicals were from Sigma Aldrich and used without further 
purification.
NMR spectra were recorded on Bruker Avance III HD 400 MHz 
or Bruker 500 MHz spectrometers; the residual signal of the solvent 
was used as a reference. ESI-MS spectra were recorded on an 
Agilent 6130B single quadrupole detector instrument and ESI-HR-
MS data were collected on a Bruker microTOF instrument at 298 
K with a scan range of m/z 50-2000 for positive ions. Samples were 
prepared in methanol or aqueous solution. Electronic absorption 
spectra were recorded on a Varian Cary 300 UV-vis 
spectrophotometer in a quartz cuvette and referenced to neat 
solvent. The spectral width was 200–800 nm and the bandwidth 
was 1.0 nm, the scan rate was set to 600 nm/min. Analytical 
reversed-phase HPLC analyses were carried out on an Agilent 
ZORBAX Eclipse XDB-C18 column (250×4.6 mm, 5 μm, flow 
rate: 1 mL/min), by using linear gradients of 0.1% TFA in H2O 
(solvent A) and 0.1% TFA in CH3CN (solvent B). LC-MS were 
carried out on Bruker Amazon X connected online with a HPLC. 
The light sources used for photoactivation were a LZC-ICH2 
photoreactor (Luzchem Research Inc.) equipped with a temperature 
controller and 8 Luzchem LZC-420 lamps without light filtration, 
and KiloArcTM broadband arc lamp monochromator supplied with 
the appropriate filters to cut off any unwanted light. An LED light 
source with λmax = 465 nm was used for in vitro growth inhibition 
and cell cycle assays. Platinum contents were analysed on an ICP-
OES 5300DV (Perkin Elmer) or ICP-MS 7500cx (Agilent). The 
emission wavelengths detected for Pt were 265.945, 214.423, 
299.797, 204.937 and 193.700 nm. 
Synthesis and characterization. Caution! Heavy metal azides 
can be shock-sensitive detonators. We did not encounter any 
problems during the work reported here, but due care and attention 
with appropriate precautions should be taken in their synthesis and 
handling. All synthesis and purifications were carried out in the 
dark with minimal light exposure.
General synthesis procedure for complexes 1–4. To a solution of 
trans, trans, trans-[Pt(N3)2(OH)(succinate)(py)2] (24.4 mg, 42.8 
µmol) and TBTU (11.8 mg, 36.8 µmol) in freshly degassed 
anhydrous DMF (2 mL), N, N-diisopropylethylamine (DIPEA) 
(100 µL) was added. After stirring for 3 min, a solution of 0.5 mol 
equiv of corresponding diamine, DIPEA (60 µL) and DMF (1 mL) 
was added to the resulting mixture dropwise. The reaction mixture 
was stirred overnight at 298 K under a nitrogen atmosphere. After 
evaporation to dryness, the oily residue was collected and purified 
by column chromatography on aluminium oxide (5% methanol + 
95% DCM). 
Trans, trans, trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2 
C(O)NH)}2(CH2)2] (1). Diamine = ethylenediamine. 1H NMR 
(DMSO-d6, 400 MHz): 8.81(dd, J = 5.5 Hz, J 195Pt-1H = 26.6 Hz, 
8H, Hα py), 8.26 (t, J = 7.5 Hz, 4H, Hγ py), 7.82 (t, J = 7.0 Hz, 8H, 
Hβ py), 7.75 (t, J = 5.7 Hz, 2H, CONH), 3.66 (s, 2H, OH), 3.05 (s, 
4H, CH2), 2.46 (t, J = 7.6 Hz, 4H, CH2), 2.22 (t, J = 7.3 Hz, 4H, 
CH2). 13C NMR (DMSO-d6, 125 MHz): 175.27 (COO), 172.08 
(CONH), 149.83 (Cα py), 142.42 (Cγ py), 126.66 (Cβ py), 38.80 
(CH2), 32.39 (CH2), 32.21 (CH2). ESI-MS [M+Na+]: 1189.2160. 
Anal. Calcd: C30H36N18O8Pt2: C 30.88, H 3.11, N 21.61. Found: C 
30.43, H 3.10, N 20.69. 
Trans, trans, trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2 
C(O)NH)}2(trans-1,2-C6H10)] (2). Diamine = trans-1,2-
cyclohexanediamine. 1H NMR (DMSO-d6, 400 MHz): 8.82(dd, J = 
5.5 Hz, J 195Pt-1H = 26.5 Hz, 8H, Hα py), 8.25 (t, J = 7.5 Hz, 4H, 
Hγ py), 7.82 (t, J = 6.9 Hz, 8H, Hβ py), 7.52 (d, J = 7.3 Hz, 2H, 
CONH), 3.66 (s, 2H, OH), 3.47 (s, 2H, CH2 cyclohexyl), 2.48-2.33 
(m, 4H, CH2), 2.26-2.10 (m, 4H, CH2), 1.74 (s, 2H, CH2
cyclohexyl), 1.62 (s, 2H, CH2 cyclohexyl), 1.18 (s, 4H, CH2
cyclohexyl). 13C NMR (DMSO-d6, 125 MHz): 175.23 (COO), 
171.68 (CONH), 149.84 (Cα py), 142.38 (Cγ py), 126.65 (Cβ py), 
55.38 (CH2 cyclohexyl), 52.50 (CH cyclohexyl), 49.06 (CH 
cyclohexyl), 32.74 (CH2), 32.58 (CH2), 32.10 (CH2 cyclohexyl), 
24.87 (CH2 cyclohexyl). ESI-MS [M+Na+]: 1243.2631. Anal. 
Calcd: C34H42N18O8Pt2: C 33.45, H 3.47, N 20.65. Found: C 33.84, 
H 3.48, N 19.14. 
Trans, trans, trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2 
C(O)NH)}2(1,4-C6H4)] (3). Diamine = p-phenylenediamine. 1H 
NMR (DMSO-d6, 400 MHz): 9.79 (s, 2H, CONH), 8.82(dd, J = 5.5 
Hz, J 195Pt-1H = 26.7 Hz, 8H, Hα py), 8.25 (t, J = 7.3 Hz, 4H, Hγ
py), 7.79 (t, J = 7.1 Hz, 8H, Hβ py), 7.50 (s, 4H, CH benzyl), 3.67 
(s, 2H, OH), 2.67 (t, J = 7.3 Hz, 4H, CH2), 2.33 (t, J = 7.6 Hz, 4H, 
CH2). 13C NMR (DMSO-d6, 125 MHz): 175.20 (COO), 170.71 
(CONH), 149.83 (Cα py), 142.39 (Cγ py), 135.10 (C benzyl), 126.64 
(Cβ py), 119.77 (CH benzyl), 33.09 (CH2), 32.13 (CH2). ESI-MS 
[M+Na+]: 1237.2138. Anal. Calcd: C34H36N18O8Pt2·Et2O: C, 
35.41; H, 3.60; N, 19.56. Found: C, 35.54; H, 3.76; N, 19.96. 
Trans, trans, trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2 
C(O)NH)}2(CH2)4] (4). Diamine = 1,4-butylenediamine. 1H NMR 
(DMSO-d6, 400 MHz): 8.82(dd, J = 5.5 Hz, J 195Pt-1H = 26.9 Hz, 
3 
8H, Hα py), 8.27 (t, J = 7.6 Hz, 4H, Hγ py), 7.83 (t, J = 7.0 Hz, 8H, 
Hβ py), 7.71 (t, J = 5.5 Hz, 2H, CONH), 3.65 (s, 2H, OH), 3.00 (m, 
4H, CH2), 2.45 (t, J = 7.3 Hz, 4H, CH2), 2.23 (t, J = 7.4 Hz, 4H, 
CH2), 1.34 (s, 4H, CH2). 13C NMR (DMSO-d6, 125 MHz): 175.28 
(COO), 171.72 (CONH), 149.84 (Cα py), 142.41 (Cγ py), 126.66 
(Cβ py), 38.69 (CH2), 32.51 (CH2), 32.21 (CH2), 27.10 (CH2). ESI-
MS [M+Na+]: 1217.2461. Anal. Calcd: C32H40N18O8Pt2: C 32.16, 
H 3.37, N 21.10. Found: C 32.44, H 3.36, N 20.30. 
X-Ray crystallography. Single crystals of 1·2MeOH and 4 were 
grown from methanol/ether at ambient temperature. A suitable 
crystal was selected and mounted on a Mitegen head with Fomblin 
oil and placed on an Xcalibur Gemini diffractometer with a Ruby 
CCD area detector. The crystal was kept at 150(2) K during data 
collection. Using Olex2,37 the structure was solved with the 
ShelXT38 structure solution program using Intrinsic Phasing and 
refined with the ShelXL39 refinement package using Least Squares 
minimisation.
Photodecomposition in solution. The photodecomposition of 
complexes 1–4 in aqueous solution was monitored by UV-Vis 
spectroscopy or LC-MS at different time intervals after irradiation 
with blue light (420 nm) at ambient temperature.
Cell culture. A number of human cell lines, parental (A2780) 
and cisplatin resistant (A2780cis) ovarian carcinoma, oesophageal 
adenocarcinoma (OE19), and normal fibroblasts cells (MRC5) 
were obtained from the European Collection of Animal Cell 
Culture (ECACC), Salisbury, UK. All cell lines used in this work 
were grown in Roswell Park Memorial Institute media (RPMI-
1640), which was supplemented with 10% v/v of foetal calf serum 
(FCS), 1% v/v of 2 mM glutamine and 1% v/v 
penicillin/streptomycin. The adherent monolayers of cells were 
grown at 310 K in a humidified atmosphere containing 5% CO2 and 
passaged regularly at ca. 80% confluence. 
Photo-dark cytotoxicity. Approximately 10000 cells were 
seeded per well in 96-well plates. Independent duplicate plates 
were used, one for dark while the other for irradiation experiment. 
The cells were pre-incubated in drug-free media with phenol red 
containing medium at 310 K for 24 h before adding different 
concentrations of the compounds to be tested prepared in phenol-
free medium. Complexes were dissolved first in DMSO and then 
diluted in phenol red-free RPMI-1640 to make the stock solution 
of the drug. These stock solutions were further diluted using 
phenol-red free cell culture medium until working concentrations 
were achieved, in these solutions the maximum DMSO 
concentration was in all cases < 0.5% v/v. Cells were exposed to 
the drugs with different concentrations for 1 h. Then one plate was 
irradiated for 1 h using blue light (4.8 mW cm-2 per LED at 465 
nm) while the dark plate was kept in the incubator. After 
irradiation, supernatants of both plates were removed by suction 
and washed with PBS buffer. Photocytotoxicity was determined 
after another 24 h recovery at 310 K in drug-free phenol red-
containing medium by comparison to untreated controls which 
were only exposed to vehicle. Untreated controls were also 
compared between the irradiated and the non-irradiated plates to 
ensure that the differences in cell survival were not statistically 
relevant, hence guaranteeing that the differences in cell viability 
observed were not due to the light source. The SRB assay was used 
to determine cell viability.40 Absorbance measurements of the 
solubilised dye (on a Promega microplate reader, 510 nm) allowed 
the determination of viable treated cells compared to untreated 
controls. IC50 values (concentrations which caused 50% of cell 
death), were determined as the average of triplicates and their 
standard deviations were calculated. Stock concentrations for all 
metal complexes used in these biological assays were 
adjusted/verified after ICP-OES metal quantification. 
Platinum accumulation in cancer cells. For Pt cellular 
accumulation studies, ca. 4.5×106 A2780, A2780cis and OE19 
cells were plated in 100 mm Petri dishes and allowed to attach for 
24 h. Then the plates were exposed to complexes at equipotent 
concentrations equal to the photoactive IC50 values in the 
corresponding cell line. Additional plates were incubated with 
medium alone as a negative control. After 1 h of incubation in the 
dark at 310 K, the cells were rinsed three times with cold 
phosphate-buffered saline (PBS) and harvested by trypsinisation. 
The number of cells in each sample was counted manually using a 
haemocytometer. Then the cells were centrifuged to obtain the 
whole cell pellet for ICP-MS analysis. All experiments were 
conducted in triplicate. 
ICP-MS sample preparation. The whole cell pellets were 
dissolved in concentrated 72% v/v nitric acid (200 μL), and the 
samples were then transferred into wheaton v-vials (Sigma-
Aldrich) and heated in an oven at 343 K overnight. The vials were 
then allowed to cool, and each cellular sample solution was 
transferred into a vial and diluted with Milli-Q water (3.8 mL), to 
obtain a final HNO3 concentration of ca. 3.6% v/v. 
Photoreactions with 5′-GMP. 2, 4 or 8 mol equiv of guanosine 
5′-monophosphate disodium salt hydrate (5′-GMP-Na2) was mixed 
with 30 μM complex 4 in methanol:water 5:95 v/v. The solution 
was incubated at 310 K for 1 h then irradiated for 1 h and analysed 
immediately. HPLC analysis was carried out on an Agilent 
ZORBAX Eclipse XDB-C18 column (250 × 4.6 mm, 5 μm, flow 
rate: 1 mL/min). The mobile phases for HPLC were A (0.1 % 
formic acid in HPLC grade H2O, volume percentage) and B (0.1 % 
formic acid in HPLC grade acetonitrile, volume percentage). The 
Pt adducts were isolated and analysed by Bruker Amazon X 
connected online with the HPLC. 
Electron paramagnetic resonance (EPR) spectroscopy. The 
EPR spectra were recorded on a Bruker EMX (X-band) 
spectrometer at 298 K. Samples (ca. 100 μL) in aqueous solution 
were prepared and transferred using a plastic syringe with metal 
needle to a standard quality quartz tube with inner diameter of 1.0 
mm and outer diameter of 2.0 mm (Wilmad LabGlass) and sealed 
with parafilm. Using the y-incremental sweep mode of 120 with an 
accumulation of 5 scans in the x dimension, Typical key EPR 
spectrometer settings were modulation amplitude 2.0 G, 
microwave power 1.37 mW, 1.0 ×105 receiver gain, conversion 
time 5.12 ms, time constant 5.12 ms, sweep width 200 G. The 
LED465E light irradiation source was mounted within the EPR 
magnet, supported by a foam sponge, to maintain its position 
throughout the EPR measurements. The distance from the tip of the 
irradiation light bulb to the EPR cavity was ca. 3 cm. Data were 
processed by Matlab R2016b with easyspin 5.1.12 through a 
multicomponent fit.
Flow cytometry. All flow cytometry experiments were carried 
out using a Becton Dickinson FACScan Flow Cytometer in the 
School of Life Sciences at Warwick University. Typically, cells 
were seeded in 6-well plates using 1.5 × 106 cells per well. 
Experiments included 24 h of pre-incubation in drug-free media at 
310 K in CO2 humidified atmosphere, followed by 1 h of drug 
exposure under the same conditions. After this, samples were 
irradiated for 1 h. For comparison, the dark plates were kept in the 
incubator for another 1 h.  Supernatants were removed, cells were 
washed with PBS. Samples were then collected after trypsinization, 
washed with PBS and stained in the dark with a mixture of 
propidium iodide and RNAse. After 30 min staining, cell samples 
were washed and set up for flow cytometry reading on the red 
channel FL-2. 
Kinetics of binding to ct-DNA. ct-DNA was mixed with 
complexes in 10 mM NaClO4 and immediately irradiated (visible 
light, λmax = 455 nm) for 60 or 120 min and then kept at 310 K in 
4 
the dark. The ri value was 0.05-0.08. Aliquots were removed at 
various time intervals and quickly filtered using a Sephadex G-50 
column to remove free (unbound) Pt. The Pt content in these DNA 
samples (rb, defined as the number of the molecules of platinum 
complex coordinated per nucleotide residue) was determined by 
AAS and concentration of DNA by UV-vis spectroscopy.
Characterization of DNA Adducts of Photoactivated 
complexes by EtBr Fluorescence. ct-DNA was incubated with the 
Pt complexes under irradiation conditions (visible light, λmax = 455 
nm for 2 h and subsequently incubated in the dark for an additional 
23 h) at various rb values in 10 mM NaClO4 at 310 K. Fluorescence 
measurements of ct-DNA modified by Pt complexes in the 
presence of EtBr were performed at an excitation wavelength of 
546 nm, and the emitted fluorescence was analyzed at 590 nm. The 
fluorescence intensity was measured in NaCl (0.4 M) to avoid 
secondary binding of EtBr to DNA. The concentrations were 0.01 
mg mL−1 for DNA and 0.04 mg mL−1 for EtBr, which corresponded 
to the saturation of all binding sites for EtBr in DNA. The 
fluorescence spectra were recorded by a Varian Cary Eclipse 
spectrofluorophotometer using a 0.5 cm quartz cell at room 
temperature.
Formation of interstrand cross-links. Solutions of the plasmid 
pUC19 linearized by EcoRI (50 μg mL−1) were incubated with the 
Pt complex under irradiation conditions (for 1 h and subsequently 
incubated in the dark for an additional 23 h) at various ri values in 
NaClO4 (10 mM) at 310 K. Autoradiograms were recorded of 
denaturing 1% agarose gel of linearized DNA which was 3′-end 
labeled and nonmodified or modified by FM-190, 1 and 4
photoactivated by visible light. 
Transcription mapping of platinum-DNA adducts.
Transcription of the (NdeI/HpaI) restriction fragment of pSP73KB 
DNA modified by cisplatin, transplatin or 1, 4 and FM-190 in the 
dark or photoactivated by visible light (λmax = 455 nm for 1 h and 
subsequently incubated 23 h in the dark, 310 K, 10 mM NaClO4) 
with DNA-dependent T7 RNA polymerase and electrophoretic 
analysis of transcripts was performed according to the protocols 
recommended by the manufacturer (Promega Protocols and 
Applications, 43−46, 1989/90) and described in detail previously.19
The concentration of DNA in this assay was 1.54 × 10−4 M (relative 
to the monomeric nucleotide content). The ri values for platination 
reactions were chosen so as to obtain an rb value in the range 0.001 
– 0.01. Pt complexes not bound to DNA were removed by ethanol 
precipitation. 
Unwinding of Negatively Supercoiled DNA. Negatively 
supercoiled pSP73KB plasmid was treated with FM-190, 1 or 4
photoactivated by visible light (λ = 420 nm) for 1 h and incubated 
for 23 h at 310 K in the dark. The degree of supercoiling was 
monitored using electrophoresis in 1% native agarose gel. The 
unwinding angle is given by Φ = −18σ/rb(c), where σ is the 
superhelical density (-0.063), and rb(c) is the value of rb at which 
the supercoiled and nicked forms comigrate. 
DNase I Footprinting. Supercoiled pSP73 plasmid was digested 
with Hind III restriction endonuclease and 3′-end-labeled by 
treatment with Klenow exo- and [α-32P]-deoxy-ATP. After 
radioactive labelling, the DNA first cleaved with Hind III was 
further digested with Nde I to yield 158 and 2306 bp fragments. 
The 158 bp fragment was purified by 1% agarose gel 
electrophoresis and isolated from the gel by a Promega Wizard SV 
Gel cleanup system. 
Radioactively labelled DNA (5.4×10-6 M) and the Pt complex (ri
= 0.1, 0.2, 0.4) in 10 mM NaClO4 was irradiated by λ = 420 nm for 
1 h and incubated for 23 h at 310 K in the dark. Radioactively 
labelled DNA and the Pt complex at ri = 0.4 were also incubated in 
the dark for 24 h at 310 K. The reaction mixture was then 
lyophilized and dissolved in 9 μL solution containing a 1.11 × 
TKMC buffer (10 mM Tris, pH 7.9, 10 mM KCl, 10 mM MgCl2, 
and 5 mM CaCl2) and 3 μg ct-DNA. Cleavage was initiated by the 
addition of 0.25 U of DNase I (one unit of RQ1 RNase-Free DNase 
is defined as the amount required to completely degrade 1 μg of 
lambda DNA in 10 min at 310 K in 50 μL of a buffer containing 40 
mM Tris-HCl (pH 7.9), 10 mM NaCl, 6 mM MgCl2 and 10 mM 
CaCl2) and allowed to react for 30 s at 298 K before quenching with 
2.5 μL of a DNase stop solution (3 M NaOAc and 0.25 M EDTA). 
This was then precipitated with ethanol, lyophilized, and 
resuspended in a formamide loading buffer. DNA cleavage 
products were resolved by poly(acrylamide) (PAA) gel 
electrophoresis under denaturing conditions (8%/8 M urea PAA 
gel). The autoradiograms were visualized and quantified by using 
a bioimaging analyzer. Assignment of the cleavage to a particular 
base has been made so that it corresponds to cleavage of the 
phosphodiesteric bond on the 5′ side of that base. 
RESULTS AND DISCUSSION 
Synthesis and characterization of complexes 1–4. The 
synthetic route for dinuclear PtIV complexes 1–4 is summarized in 
Scheme 1. The mononuclear complexes trans, trans, trans-
[Pt(N3)2(OH)2(py)2] (FM-190) and trans, trans, trans-
[Pt(N3)2(OH)(OC(O)CH2CH2C(O)OH)(py)2] (FMSA) were 
prepared by similar procedures to those reported.26 The two PtIV
centers with axial succinate carboxylates were coupled through 
amide bond formation using bridging diamines containing ethylene 
(1), 1,2-cyclohexyl (2), 1,4-phenylene (3), or butyl (4) linkers. 
Complexes 1–4 are air-stable at ambient temperature, both in the 
solid state and in aqueous solution. They gave satisfactory 
elemental analysis and were further characterized by ESI-MS, 
NMR and UV/Vis spectroscopy, and for complexes 1 and 4 by x-
ray crystallography. 
The 1H and 13C NMR spectra of complexes 1–4 in DMSO-d6
contain the expected peaks (Figures S1–S8). In the 1H NMR 
spectra, the doublets with 195Pt satellites at ca. 8.82 ppm (J = 5.5 
Hz, J 195Pt-1H = 26.6 Hz) and the triplets at ca. 8. 26 ppm (J = 7.5 
Hz), 7.82 ppm (J = 7.0 Hz) are assigned to the Hα, Hγ and Hβ of 
pyridine, respectively. The peaks at ca. 3.66 ppm are assignable to 
the resonances of the hydroxyl protons and the peaks at 7.52-9.79 
ppm to the amide protons. The 13C NMR resonances of complexes 
1–4 at ca. 149.83, 142.40 and 126.66 ppm are attributable to the
Cα, Cγ and Cβ carbons of pyridine, respectively. The complexes all 
display peaks at ca. 175.27 and 172.00 ppm for the carboxyl and 
amide carbons, respectively. The electronic absorption spectrum of 
complex 1 is similar to that of its mononuclear analogue trans, 
trans, trans-[Pt(N3)2(OH)2(py)2]. In water/methanol (2:3) solution, 
complex 1 shows a high-energy band at 262 nm (ε = 25260 M-1cm-
1) and a maximum absorption band at 300 nm (34109 M-1cm-1), 
which are assigned to a LMCT (OH→Pt, N3→Pt) transition. In 
addition, a weak band is observed at 420 nm that has mixed 
1LMCT/1IL character and involves N3 and OH ligands and 
platinum.21 This band enables the photoactivation of complex 1
using blue light. Complexes 2–4 show similar electronic absorption 
spectra as complex 1, except that the high-energy band (at 260 nm, 
ε = 49189 M-1cm-1) of complex 3 is more intense than those of its 
analogues (ε ≈ 25000 M-1cm-1), owing to the absorption of the 
phenyl fragment. 
X-ray crystallography. Crystals suitable for X-ray diffraction 
studies of complexes 1·2MeOH and 4 were obtained through the 
diffusion of diethyl ether into corresponding solutions in methanol. 
The structure of complexes 1·2MeOH and 4 are shown in Figure 1. 
The crystallographic data are summarized in Table S1 and selected 
bond distances and angles are listed in Table 1. Complex 1·2MeOH 
crystallized in the triclinic space group P-1 with one complex and 
two methanol molecules in the unit cell. Complex 4 crystallized in 
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Scheme 1. The synthetic route for photoactive dinuclear diazido platinum(IV) complexes 1–4. 
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the monoclinic space group P21/n with two molecules in the unit 
cell. 
Complexes 1·2MeOH and 4 are neutral and consist of two 
mononuclear PtIV fragments bridged by an aliphatic linker of a 
diamine which forms amide bonds to the axial succinate 
carboxylates. The two Pt centers are symmetric with the diamine 
linker sitting on an inversion center. The geometries of the Pt 
centers are similar to their mononuclear analogue trans, trans, 
trans-[Pt(N3)2(OH)2(py)2]: octahedral with [N4O2] coordination. 
The equatorial plane is defined by four nitrogen atoms, two from 
the trans pyridine molecules and two from the trans azides. An 
oxygen atom from a hydroxido ligand is located in an axial 
position, while the other axial position is occupied by an oxygen 
from one of the succinate carboxylate groups. 
Figure 1. X-ray crystal structures of 1·2MeOH (A) and 4 (B). The 
complexes sit on inversion centers and only the asymmetric unit is 
labelled. Thermal ellipsoids are drawn at the 50% probability level. 
Compared with the fully symmetrical complex trans, trans, 
trans-[Pt(N3)2(OH)2(py)2], complexes 1·2MeOH and 4 exhibit 
distortions from ideal octahedral geometry. The axial bond angles 
between PtIV and trans donor atoms are <180° and the Pt-O 
(hydroxide, 1.9857(18) Å) bond is slightly shorter than Pt-O 
(succinate, 2.0185(18) Å), which can be attributed to the steric 
hindrance caused by the relatively bulky carboxylate groups. The 
azido ligands are almost linear with the Pt-N(α)-N(β) angles 
slightly smaller than 120°. The terminal azide N-N bond (1.140(4) 
and 1.138(4) Å) is slightly shorter than the azide N-N bond 
(1.211(3) and 1.220(3) Å) closest to Pt, which is typical of azide 
ligands due to their resonance structure. The Pt-N(pyridine) bond 
(2.030(2) and 2.038(2) Å) is shorter than the Pt-N(azide) bond 
(2.053(2) and 2.052(2) Å). The amide C=O distances are 1.240(3) 
and 1.236(5) Å, while those in the ester group are 1.216(3) and 
1.217(4) Å, which resemble typical carbonyl groups in their 
mononuclear analogues.25 Weak hydrogen bonds are observed in 
complexes 1·2MeOH and 4 (Table S2, detailed description in the 
Supporting Information). 
Table 1. Selected Bond Lengths (Å) and Bond Angles (°) for 
1·2MeOH and 4. 
1·2MeOH 4 
Pt1–O1 1.9857(18) Pt1–O1 1.969(3) 
Pt1–N1 2.030(2) Pt1–N1 2.030(3) 
Pt1–N7 2.038(2) Pt1–N7 2.033(3) 
Pt1–O13 2.0185(18) Pt1–O13 2.059(3) 
Pt1–N20 2.053(2) Pt1–N21 2.048(4) 
Pt1–N23 2.052(2) Pt1–N24 2.052(3) 
N20–N21 1.211(3) N21–N22 1.183(5) 
N21–N22 1.140(4) N22–N23 1.163(6) 
N23–N24 1.220(3) N24–N25 1.217(5) 
N24–N25 1.138(4) N25–N26 1.137(5) 
O1–Pt1–O13 174.49(7) O1–Pt1–O13 170.35(11) 
N21–N20–Pt1 114.52(18) N22–N21–Pt1 114.3(3) 
N22–N21–N20 175.0(3) N23–N22–N21 175.6(5) 
N24–N23–Pt1 113.68(18) N25–N24–Pt1 120.4(3) 
N25–N24–N23 175.6(3) N26–N25–N24 174.4(4) 
Figure 2. Photochemical decomposition with blue light (420 nm) 
of 1 (5×10-5 M, in H2O: methanol 1:2 v/v) determined by UV/vis 
spectroscopy (Insert: time dependence of absorbance change at 300 
nm). 
Photoactivation. The photodecomposition of complexes 1–4 in 
aqueous solution was monitored by UV-vis spectroscopy at various 
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time intervals after irradiation with blue light (420 nm) at ambient 
temperature. Figure 2 shows the decrease in absorbance maximum 
of complex 1 at ca. 300 nm, assigned as the N3→Pt LMCT band. 
The decrease indicates the release of the azide ligands was 
complete within 1 h. This photodecomposition behaviour is similar 
to that of the mono-Pt counterpart. Similar results were obtained 
for the other three complexes (Figure S9). Photoreactions of 
dinuclear complex 4 were investigated by LC-MS (Figure S10 and 
Table S3). The HPLC peak assigned to complex 4 disappeared 
within 10 min of irradiation with blue light (420 nm). Peaks 
assignable to dinuclear photoproducts increased in intensity 
gradually and peaked after 5 min, and then decreased over 30 min 
with a concomitant increase in the formation of mononuclear 
photoproducts [{PtII(py)2(OC(O)H)2}+Na]+ (466.05) and 
{PtII(CH3CN)(N3)(py)2}+ (436.10). It appears that complex 4 loses 
one azide from both platinum centers initially, followed by the 
dissociation of a platinum center and the associated bridging ligand 
(Figure S10). 
Figure 3. Observed (black) and simulated (red) EPR spectra of 
complex 4 in aqueous solution with 5% DMSO showing the 
formation of DMPO–N3• and DMPO–OH• adducts after irradiation 
(465 nm). The experimental trace is the accumulation of 500 scans 
(conversion time 5.12 ms, time constant 5.12 ms, sweep time 10.48 
s for each scan) with continuous irradiation (465 nm). Parameters 
for simulation: DMPO-N3• (g = 2.00583,       = 14.5 mT,   
 = 14.2 
mT,       = 0.31 mT); DMPO-OH• (g = 2.0058,       = 14.5 mT, 
  
 = 14.2 mT). 
Formation of azidyl radicals. The formation of azidyl radicals 
from the photodecomposition of these PtIV complexes was 
monitored by EPR using DMPO as a spin trap. EPR spectra were 
recorded continuously for 5 mM solution of complex 4 and 40 mM 
DMPO in 5% DMSO/95% H2O on irradiation with blue light (465 
nm, 20 mW) at 298 K. Both azidyl and hydroxyl radical adducts of 
DMPO (DMPO–N3• and DMPO–OH•) were detected upon 
irradiation, as a 1 : 2 : 2 : 1 quartet of triplets and a 1 : 2 : 2 : 1 
quartet, respectively (Figure 3). The simulation was carried out 
using the parameters listed in Figure 3, which is in accordance with 
reference.23
Photocytotoxicity and cellular accumulation studies. Upon 
irradiation with blue light (465 nm, 4.8 mW/cm2, 1 h), complexes 
1–4 exhibited photocytotoxicity towards several human cancer cell 
lines, including A2780, A2780cis ovarian and OE19 oesophageal 
cancer cells. The dose-dependent inhibition of cell viability 
determined by the sulforhodamine B (SRB) colorimetric assay both 
in the dark and after irradiation of complexes 1–4, is summarised 
in Table 2. In parental (A2780) and cisplatin resistant (A2780cis) 
ovarian carcinoma, complexes 1–4 showed no cytotoxicity in the 
dark. However, upon irradiation for 1 h, complexes 1–4 exhibited 
cytotoxicity to varying extents. Complex 4 was the most potent 
member of the series (IC50 = ca. 17.0 μM for ovarian cancer cells 
A2780 and A2780cis, and 8.8 μM for OE19) with photocytotoxic 
index (PI) towards cancer cells > 6 for ovarian carcinoma and 11 
for oesophageal adenocarcinoma with light exposure. Complexes 1
and 3 had lower IC50 values toward the cisplatin-resistant A2780cis 
cell line (IC50 = 29.5 μM (1), 35.5 μM (3)) compared to the parental 
A2780 cell line (IC50 = 77.0 μM (1), 78.3 μM (3)), which suggests 
a different mechanism of action from cisplatin and the possibility 
of overcoming the resistance. In contrast, the mononuclear 
analogue FM-190 was 10x more toxic to parental A2780 (1.4 μM) 
compared with cisplatin resistant A2780cis (14.5 μM) cells upon 
irradiation with UVA (365 nm).21 Complexes 1–4 displayed 
cytotoxicity towards OE19 both in the dark and upon irradiation. 
However, irradiation improved the cytotoxicity slightly for 
complexes 1–3, and considerably so for 4, with a photocytotoxic 
index (PI) >11 (IC50 = 97.0 μM (dark), 8.8 μM (light)).  
In contrast to the photocytotoxicity observed towards cancer cell 
lines, complexes 1–4 were relatively non-toxic toward the normal 
cell line MRC5, with IC50 values >100 μM, even after irradiation 
(Table 2). Since azidyl and hydroxyl radicals generated from 
platinum(IV) complexes with azides are key species involved in 
cell death,23 their relative non-cytotoxicity towards MRC5 may be 
due to the lower basal ROS level of healthy cells, with higher 
radical levels being needed to cause cell death.41 For comparison, 
cisplatin tested under the same conditions induced little 
cytotoxicity in all cell lines due to the short incubation time (1 h, 
IC50 >100 μM with or without light). 
Cellular accumulation is related to the molecular structure as 
well as the lipophilic nature of the complex and often correlates 
with the antiproliferative activity of metallodrugs. The extent of 
cellular uptake of complexes 1–4 was investigated by treating 
cancer cell lines with IC50 concentrations for 1 h in the dark. The 
cell accumulation of Pt was then determined by ICP-MS. As shown 
in Table 3, complex 3 exhibited > 5x higher Pt accumulation than 
other complexes in all cell lines, attributable to its aromatic bridge 
linker and higher lipophilicity. For complexes with aliphatic 
linkers, 1 showed slight higher levels of Pt accumulation in all 
cancer cell lines compared with complexes 2 and 4. It is notable 
that accumulation of Pt from complex 4 in cisplatin-resistant 
A2780cis ovarian cancer cells is 2x that for the parental A2780 cell 
line, even though complex 4 is equally toxic to both cell lines. 
These results appear to support the ability of the dinuclear 
complexes to overcome resistance to cisplatin. 
Cell cycle analysis. The effect of complexes 3 and 4 in the 
presence of light on the progression of the cell cycle was studied. 
Cells were exposed to prodrugs at equipotent photocytotoxic IC50
concentrations for 1 h in the dark, then irradiated for 1 h (465 nm, 
4.8 mW/cm2, 1 h). After 24 h recovery, cells were stained in the 
dark with propidium iodide in the presence of RNAse then analysed 
by flow cytometry. The results are summarised in Table S4 and 
Figure 4. 
In all cancer cell lines, the populations of cells in the stages of 
the cycle were not affected by the complexes in the dark, but 
changed dramatically upon irradiation. In OE19 oesophageal 
cancer cells, a reduction of cells in the G0/G1phase was observed 
(ca. 45% to 29 %), paralleled by an accumulation of cells in the 
G2/M phases (ca. 36% to 57 %), suggesting that dinuclear 
complexes 3 and 4 inhibit progression from G2/M to G0/G1 upon 
irradiation. 
7 
Table 2. IC50 values and photocytotoxic index (PI) for complexes 1–4 obtained after 1 h incubation, 1 h irradiation (465 nm) and 24 h 
recovery. CDDP (cisplatin) and CPZ (chlorpromazine) were used as references. 
Cell IC50 (μM)a
1 2 3 4 CDDP CPZ FM-190 
A2780 Dark > 100 > 100 > 100 > 100 > 100 > 100 > 100 
Irrad 77.0 ±2.9 33.9±5.2 78.3±6.8 16.7±3.3 > 100 6.0±0.3 7.1±0.4 
PI >1.3 >2.9 >1.3 >6.0 - >16.7 > 14.0 
A2780cis Dark > 100 > 100 > 100 > 100 > 100 51.0±0.2 
Irrad 29.5±11.0 67.6±15.7 35.5±3.4 17.0±2.3 > 100 6.0±0.3 
PI >3.4 >1.5 >2.8 >5.8 - 8.5 
OE19 Dark 41.3±3.2 49.8±1.5 53.4±0.4 97.0±5.7 > 100 
Irrad 36.2±2.4 27.5±5.1 43.7±1.9 8.8±0.9 > 100 
PI 1.1 1.8 1.2 11.0 - - 
MRC5 Dark > 100 > 100 > 100 > 100 > 100 > 100 > 100 
Irrad > 100 > 100 > 100 > 100 > 100 > 50 > 100 
a Data are from three independent experiments.  
Table 3. Cell accumulation of Pt (ng/106 cells) in cancer cells after exposure to complexes 1–4 (equipotent IC50 concentration, 1 h, in 
dark).  
Complex Platinum accumulation (ng/106 cells) 
A2780 A2780cis OE19 
1 24 ±8* 17±6* 13±1*
2 10±2* 11±2** 12±2**
3 101±6* 56±17* 51±5***
4 8±1* 17±2* 8±2*
FM-190 0.8±0.2*
a All data were determined from triplicate samples and their statistical significance evaluated by a two-tail t-test with unequal variances. 
*p < 0.05, **p < 0.01, ***p < 0.005.
Photoactivated complex 4 induced more significant changes in the 
cell cycle progression compared with 3 (two-tail t-test with unequal 
variances against control, Table S4), consistent with the higher 
photocytotoxicity of complex 4. Similar changes in cell cycle 
populations were found for A2780 and A2780cis ovarian cancer 
cells (Figure 4). This is in contrast to cisplatin which arrests cells 
in S phase,42 suggesting a different mechanism of action and a lack 
of cross-resistance between complexes 3 and 4 and cisplatin. 
Photoinduced reactions with 5′-guanosine monophosphate (5′-
GMP). Since the N7 site of the DNA base guanine is a preferred 
target for platinum amine anticancer complexes, photoreactions of 
complex 4 with 5′-guanosine monophosphate were investigated. 
The photoreactions were carried out by irradiating solutions of 
complex 4 (30 μM) in 5% methanol/95% water v/v in the presence 
of 5’-GMP (2, 4 or 8 mol equiv.) with blue light (420 nm) at 310 K 
and monitored by reverse-phase HPLC (Figure S11, Table S5). The 
photorelease of the bridging ligand 
[HOOC(CH2)2C(O)NH(CH2)4NHC(O)(CH2)2COOH+H]+
(289.21) was confirmed by LC-MS and the amount released did not 
change significantly when the ratio of 5′-GMP/Pt was increased. 
The major photoproduct is assignable as {PtII(CH3CN)(py)2(GMP-
H)}+ (756.09), which increased in proportion at higher 5′-GMP 
ratios. In addition, two small peaks ascribed to 
{PtII(N3)(py)2(GMP)}+ (757.95) and {PtII(OC(O)H)(py)2(GMP)}+
(761.91) were detected. {PtII(OC(O)H)(py)2(GMP)}+  was formed 
due to the addition of formic acid in mobile phase of LC-MS. 
Complex 4 reacted completely within 1 h of irradiation. The time 
dependence of the formation of photoproducts from the UV-vis 
spectra and LC-MS data is shown in Figure S12. Even though the 
decomposition of complex 4 can be detected within only 1 min of 
irradiation, the apparent decrease of the absorbance of 5′-GMP and 
the formation of {PtII(CH3CN)(py)2(GMP-H)}+ (756.09) is 
observed only after 5 min of irradiation. No dinuclear photoproduct 
with 5′-GMP was detected, which suggests that the Pt centers do 
not react with 5′-GMP until they are detached from the bridging 
ligands. The results above agree well with those previously 
reported for the parent complex and its succinate derivative, 
suggesting that the two PtIV centers have little effect on each other 
during the photoreactions with 5′-GMP. 
DNA binding studies in cell-free media. To further explore the 
differences between mono- and di-nuclear complexes, and the 
effect of bridge linkers, the DNA binding ability of photoactivated 
dinuclear complexes 1 and 4 was investigated in comparison with 
mononuclear FM-190. 
Ct-DNA was mixed with complexes in 10 mM NaClO4 and 
immediately irradiated with blue visible light (λmax = 455 nm) for 1 
h then kept at 310 K in the dark. Aliquots were removed at various 
time intervals and quickly filtered using a Sephadex G-50 column 
to remove free (unbound) Pt. The Pt content in these DNA samples 
was determined by AAS and the concentration of DNA was 
determined by UV-vis to give the kinetics of Pt binding to ct-DNA. 
The amount of Pt bound to DNA increased with time for all 
complexes. No significant difference was found between the 
investigated complexes (Figure 5A). 
The DNA intercalator EtBr was used as a fluorescent probe to 
characterize perturbations induced in DNA by the adducts with Pt 
complexes. Modification of DNA by platinum complexes under 
irradiation conditions resulted in a decrease of EtBr fluorescence. 
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Figure 4. Flow cytometry histograms showing cell cycle analysis of A2780, A2780Cis ovarian and OE19 oesophageal cancer cells. (■ Dark, 
■ Irradiated) In all cases, the experiments involved 1 h of drug exposure followed by 1 h of either irradiation (465 nm) or darkness. PI = 
Propdium Iodide. 
The decrease caused by the adducts of photoactivated 1 or 4 was 
double than that induced by the DNA adducts of FM-190 at 
equivalent rb values (Figure 5B).It was also verified that irradiation 
of ct-DNA by visible light in the absence of complexes for 2 h had 
no effect on EtBr fluorescence. The results of these experiments 
suggest that the conformational distortions induced in DNA by the 
adducts formed by the treatment of DNA with irradiated 1 and 4
are delocalized and extend over the base pairs around the 
platination sites to an extent which corresponds to the distortions 
induced in DNA by two adducts of mononuclear FM-190. Thus, 
these results are consistent with the decomposition of the dinuclear 
complexes 1 and 4 due to irradiation resulting in the release of two 
mononuclear fragments similar to those from FM-190. 
It was shown previously43 that modification of DNA by irradiated 
FM-190 resulted also the formation of DNA interstrand cross-
links. Therefore, we investigated the capability of irradiated 1 and 
4 to form DNA interstrand cross-links as well. Plasmid pUC19 
linearized by EcoRI (50 μg mL−1) and the platinum complex were 
irradiated with blue light for 1 h and subsequently incubated in the 
dark for an additional 23 h in NaClO4 (10 mM) at 310 K. The 
plasmid was modified to the extent corresponding to the rb values 
of 0.003 and 0.0006 (in the case of FM-190) or 0.00015 and 0.0003 
(in the case of 1 and 4) and analyzed by agarose gel electrophoresis 
under denaturing conditions (Figure 5C). Interstrand crosslinked 
DNA appears as the top band (marked as ICLs) migrating on the 
gel more slowly than single-stranded DNA (contained in the 
bottom bands and marked as ss). The quantitative evaluation of the 
radioactivity associated with the individual bands showed that 
irradiated 1 and 4 formed two-fold amount of the interstrand 
crosslinks in DNA than FM-190 (the frequency of interstrand 
crosslinking was 12.5 ± 0.5, 24 ± 2 and 24 ± 2 for FM-190, 1 and 
4, respectively) at the same level of modification (related to the 
complex). Hence, the results of DNA interstrand cross-linking 
experiments also support the hypothesis that the irradiation of the 
dinuclear complexes 1 and 4 leads to their decomposition resulting 
in the release of two molecules similar to the photoproduct from 
mononuclear FM-190. Our previous work suggested that the trans-
{Pt(py)2}2+ fragment released from FM-190 can form GG 
interstrand DNA cross-links, including 5′-CG/5′-CG cross-links, 
5′-GC/5′-GC cross-links and cross-links between G and the 
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complementary C.44 It is, therefore, reasonable to envisage that 
treatment of DNA by irradiated dinuclear 1 or 4 results in the 
formation of trans GG interstrand DNA cross-links as in the case 
of the treatment with mononuclear FM-190. 
It has been shown that the binding of various antitumor 
metallodrugs to closed circular DNA can cause partial unfolding of 
the DNA. This process lowers the superhelical density of plasmid 
DNA, which causes a decrease in the rate of migration through an 
agarose gel. This fact makes it possible to observe and quantify the 
mean value of unwinding per adduct. In the present study, we 
investigated the unwinding induced in negatively supercoiled 
pSP73KB plasmid by 1, 4 photoactivated by visible light (λ = 420 
nm) for 1 h, then incubated for another 23 h at 310 K in the dark. 
The degree of supercoiling was monitored using electrophoresis in 
a native agarose gel. We investigated the effect of increasing 
amounts of the investigated platinum complexes photoactivated by 
visible light bound to a mixture of relaxed and supercoiled 
pSP73KB DNA on migration of these forms in a native agarose gel 
(shown in Figure 5D). The unwinding angle is given by Φ = 
−18σ/rb(c), where σ is the superhelical density, and rb(c) is the value 
of rb (related to the complex) at which the supercoiled and nicked 
forms comigrate. The DNA unwinding angle determined for DNA 
modified by dinuclear 1 and 4 photoactivated by visible light was 
57 ± 8°. This unwinding angle was two-fold higher than that found 
under identical conditions for DNA modified by mononuclear FM-
190 (28 ± 4°).43 Thus, consistent with the results of the experiments 
aimed at characterization of DNA adducts by EtBr fluorescence 
and DNA interstrand cross-linking, the results of DNA unwinding 
experiments (Figure 5D) can be interpreted to mean that the 
consequence of the irradiation of the dinuclear complexes 1 and 4
is their decomposition resulting in the release of two molecules of 
mononuclear FM-190. 
A parameter which makes identification of preferential DNA 
binding sites of platinum antitumor drugs possible can be obtained 
from transcription mapping experiments.45 In vitro RNA synthesis 
by RNA polymerases on DNA templates containing several types 
of bifunctional adducts of platinum complexes can be prematurely 
terminated at the level, or in the proximity, of DNA adducts. We 
prepared a 212-bp fragment by cutting of pSP73KB DNA by NdeI 
and HpaI restriction endonucleases. A substantial part of its 
nucleotide sequence is shown in Figure S13B. This fragment 
contained a T7 RNA polymerase promotor (in the upper strand 
close to its 3'-end, Figure S13B). The experiments were carried out 
using this linear DNA fragment, modified by cisplatin, transplatin 
(in the dark), or 1 or 4 photoactivated by visible light. The samples 
were irradiated for 1 h and subsequently incubated in the dark for 
additional 23 h. The rb values were in the range of 0.004 - 0.01 and 
are indicated in the legend to Figure S13A. The major stop signals 
for DNA modified by dinuclear 1 and 4 (Figure S13) were identical 
to those found previously under identical conditions for DNA 
modified by irradiated FM-190.43
In order to obtain further information on the sequence-specificity 
of DNA binding in dinuclear 1 and 4 analogues of complex FM-
190, a DNase I footprinting experiment was also performed (Figure 
S14). The details of this experiment are described in the Supporting 
information. The results show that the preferential binding sites of 
dinuclear 1 and 4 are those containing mainly G/A-rich sequences 
and are identical to those of mononuclear FM-190. Collectively, 
the results of transcription mapping and DNase I footprinting 
experiments suggest that preferential DNA binding sites of 
irradiated dinuclear 1 and 4 are similar to those of mononuclear 
FM-190 thus also supporting the hypothesis that the irradiation of 
the dinuclear complexes 1 and 4 results in their decomposition 
resulting in the release of two molecules similar to photoproducts 
from mononuclear FM-190. 
Figure 5. DNA binding of photoactivated complexes in cell-free 
media. A) Kinetics of the reaction of the investigated complexes 
photoactivated by visible light ((λmax = 455 nm) with ctDNA. For 
other details, see the text. B) Dependence of ethidium bromide 
fluorescence on rb for double-helical ctDNA modified by the 
investigated platinum complexes photoactivated by visible light 
(λmax = 455 nm) in NaClO4 (10 mM) at 37 °C for 24 h. C) Formation 
of interstrand (intramolecular) cross-links by the investigated 
platinum complexes photoactivated by visible light (λmax = 455 nm) 
in pUC19 plasmid linearized by EcoRI. Solutions of the linearized 
plasmid (50 μg mL−1) were incubated with the platinum complex 
under irradiation conditions (for 1 h and subsequently incubated in 
the dark for an additional 23 h) at various ri values in NaClO4 (10 
mM) at 37 °C. Autoradiogram of denaturing 1% agarose gel of 
linearized DNA which was 3′-end labeled and nonmodified and 
nonirradiated (kept in the dark) (lane C) or modified by 
photoactivated FM-190 (rb = 0.0003 and 0.0006, lanes 1, 2, 
respectively), 1 (rb = 0.00015 and 0.0003, lanes 3, 4, respectively), 
or 4 (rb = 0.00015 and 0.0003, lanes 3, 4, respectively). Interstrand 
crosslinked DNA appears as the top bands (marked as ICL) 
migrating on the gel more slowly than single-stranded DNA 
(contained in the bottom bands and marked as ss). D) Unwinding 
of supercoiled pSP73KB plasmid DNA by the investigated 
dinuclear platinum complexes photoactivated by visible light (λmax
= 455 nm). The top bands correspond to the nicked form of the 
plasmid and the bottom bands to the closed, negatively supercoiled 
plasmid. The plasmid was incubated with FM-190, 1 and 4 under 
irradiation conditions (for 1 h and subsequently incubated in the 
dark for an additional 23 h) at various ri values in NaClO4 (10 mM) 
at 37 °C. Lane C, control, nonplatinated and nonirradiated DNA (rb
= 0); lanes 1−10, DNA modified by photoactivated complexes so 
that the resulting rb values were: for FM-190: 0.001, 0.003, 0.005, 
0.010, 0.015, 0.020, 0.025, 0.030, 0.035 and 0.040 respectively; for 
1: 0.0005, 0.0025, 0.005, 0.0075, 0.01, 0.0125, 0.015, 0.0175, 0,02 
and 0,025 respectively; for 4: 0.001, 0.0015, 0.0025, 0.0035, 0.005, 
0.01, 0.015, 0.0175 and 0.02 respectively. 
CONCLUSIONS 
We report the synthesis and characterization of a series of novel 
dinuclear photoactive platinum(IV) anticancer prodrugs trans, 
trans, trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)NH)}2R] 
containing pyridine (py) and bridging dicarboxylate (R = -
CH2CH2- (1); trans-1,2-C6H10- (2); p-C6H4- (3); -
CH2CH2CH2CH2- (4)) ligands. We compared their photoreactivity 
with that of a mononuclear analogue FM-190. Azidyl and hydroxyl 
radicals and PtII species were generated during the 
photodecomposition of these dinuclear complexes. LC-MS 
10 
analyses of photoreactions of dinuclear complex 4 revealed the 
photorelease of the bridging ligand and formation of mononuclear 
photoproducts. In the presence of 5′-GMP, the PtII-5′-GMP adduct 
{PtII(CH3CN)(py)2(GMP-H)}+ (756.09) was formed upon 
irradiation. Dinuclear complexes exhibited promising 
photocytotoxicity upon irradiation with low-dose blue light (465 
nm, 4.8 mW/cm2, 1 h, 1 h) towards a series of human cancer cell 
lines, including A2780, A2780cis, and OE19, with high dark 
stability. Moreover, the dinuclear complexes were remarkably non-
toxic towards normal cells (MRC5), even after irradiation. The 
introduction of an aromatic bridging ligand enhanced cell uptake 
significantly for complex 3 when compared with the complexes 
containing an aliphatic bridge. The inhibition of progression from 
G2/M to G0/G1 stages in the cell cycle induced by dinuclear 
complexes upon irradiation suggests that DNA is a target. The 
dinuclear complexes behaved in cell-free media and after 
photoactivation similarly to the photoactivated mononuclear 
complex FM-190 in terms of the kinetics of binding to ct-DNA, 
transcription mapping and DNase I footprinting of Pt-DNA 
adducts. However, dinuclear complexes after photoactivation were 
approximately two-fold more effective in quenching fluorescence 
of EtBr bound to DNA, forming DNA interstrand cross-links and 
unwinding DNA compared to photoactivated mono=Pt analogue 
FM-190. This is consistent with photodecomposition of the 
dinuclear complexes into two molecules of mononuclear 
platinum(II) species. 
Hence, dinuclear complexes exhibit promising dark stability, 
photocytotoxicity and selectivity towards cancer cells, dependent 
on the nature of the bridging ligand. 
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Synopsis 
Novel all-trans dinuclear platinum(IV) complexes bridged by a dicarboxylate linker, highly 
stable in  the dark, generate azidyl and hydroxyl radicals on irradiation with blue light. They 
are photocytotoxic to human cancer cells, whereas cisplatin was inactive under these 
conditions, and more photoactive towards cisplatin-resistant ovarian cancer cells compared to 
wild-type cells. Remarkably, the dinuclear complexes were relatively non-toxic toward normal 
human cells. Cell cycle and DNA binding experiments suggested that DNA is a target.  
